Alcobra Ltd. is a clinical stage biopharmaceutical company focused on the development and commercialization of MG01CI, a novel non-stimulant therapy for attention deficit hyperactivity disorder (ADHD). The drug recently achieved strong positive results in a phase IIb study of adult ADHD patients. Results from the study demonstrated that MG01CI is highly effective, rapidly acting, and well tolerated. The Company plans to initiate two phase III clinical trials at multiple sites with approximately 250-300 adult ADHD patients each in 2014. Investigations to date position MG01CI as a potential first line therapy that will be especially attractive to patients who cannot tolerate, or prefer not to use commonly prescribed stimulant medications. Future studies for pediatric patients are planned, and the drug is being considered in additional disorders with cognitive impairment, including Fragile X syndrome and shift work sleep disorder.. Alcobra raised $25 million in financing from its May 2013 IPO. The Company projects this financing to cover all upcoming clinical studies of MG01CI for adult indications of ADHD.